<- Go Home
Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Market Cap
$346.2M
Volume
55.0K
Cash and Equivalents
$103.6M
EBITDA
-$30.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$16.90
52 Week Low
$5.74
Dividend
N/A
Price / Book Value
3.56
Price / Earnings
-14.43
Price / Tangible Book Value
3.56
Enterprise Value
$243.6M
Enterprise Value / EBITDA
-8.26
Operating Income
-$30.1M
Return on Equity
48.57%
Return on Assets
-31.34
Cash and Short Term Investments
$103.6M
Debt
$959.0K
Equity
$97.6M
Revenue
N/A
Unlevered FCF
-$14.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium